Literature DB >> 9510170

Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4.

J H Horspool1, P J Perrin, J B Woodcock, J H Cox, C L King, C H June, D M Harlan, D C St Louis, K P Lee.   

Abstract

Immunization with plasmids expressing specific genes (DNA or nucleic acid vaccination (NAV)) elicits robust humoral and cell-mediated immune responses. The mechanisms involved in T cell activation by NAV are incompletely characterized. We have examined the costimulatory requirements of NAV. CD28-deficient mice did not mount Ab or CTL responses following i.m. immunization with eukaryotic expression plasmids encoding the bacterial gene beta-galactosidase (beta gal). Because these mice retained their ability to up-regulate the CTLA4 receptor (a negative regulator of T cell activation), we examined CTLA4's role in the response of wild-type BALB/c mice to NAV. Intact anti-CTLA4 mAb but not Fab fragments suppressed the primary humoral response to pCIA/beta gal without affecting recall responses, indicating CTLA4 activation inhibited Ab production but not T cell priming. Blockade of the ligands for CD28 and CTLA4, CD80 (B7-1) and CD86 (B7-2), revealed distinct and nonoverlapping function. Blockade of CD80 at initial immunization completely abrogated primary and secondary Ab responses, whereas blockade of CD86 suppressed primary but not secondary responses. Simultaneous blockade of CD80 + CD86 was less effective at suppressing Ab responses than either alone. Enhancement of costimulation via coinjection of B7-expressing plasmids augmented CTL responses but not Ab responses, and without evidence of Th1 to Th2 skewing. These findings suggest complex and distinct roles for CD28, CTLA4, CD80, and CD86 in T cell costimulation following nucleic acid vaccination.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9510170

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  DNA and RNA-based vaccines: principles, progress and prospects.

Authors:  W W Leitner; H Ying; N P Restifo
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

2.  CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif.

Authors:  Cheryl H Rozanski; Adam Utley; Louise M Carlson; Matthew R Farren; Megan Murray; Lisa M Russell; Jayakumar R Nair; ZhengYu Yang; William Brady; Lee Ann Garrett-Sinha; Stephen P Schoenberger; Jonathan M Green; Lawrence H Boise; Kelvin P Lee
Journal:  J Immunol       Date:  2015-04-01       Impact factor: 5.422

3.  CD28-mediated regulation of multiple myeloma cell proliferation and survival.

Authors:  Nizar J Bahlis; Anne M King; Despina Kolonias; Louise M Carlson; Hong Yu Liu; Mohamad A Hussein; Howard R Terebelo; Gerald E Byrne; Bruce L Levine; Lawrence H Boise; Kelvin P Lee
Journal:  Blood       Date:  2007-02-20       Impact factor: 22.113

4.  Activation of natural killer T cells by alpha-galactosylceramide impairs DNA vaccine-induced protective immunity against Trypanosoma cruzi.

Authors:  Yasushi Miyahira; Masaharu Katae; Kazuyoshi Takeda; Hideo Yagita; Ko Okumura; Seiki Kobayashi; Tsutomu Takeuchi; Tsuneo Kamiyama; Yoshinosuke Fukuchi; Takashi Aoki
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

5.  Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response.

Authors:  Shinichiro Fuse; Weijun Zhang; Edward J Usherwood
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

6.  Critical contribution of CD28-CD80/CD86 costimulatory pathway to protection from Trypanosoma cruzi infection.

Authors:  Yasushi Miyahira; Masaharu Katae; Seiki Kobayashi; Tsutomu Takeuchi; Yoshinosuke Fukuchi; Ryo Abe; Ko Okumura; Hideo Yagita; Takashi Aoki
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.